Equities

Zhangzhou Pientzehuang Pharmaceutical Co Ltd

600436:SHH

Zhangzhou Pientzehuang Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)245.48
  • Today's Change-1.62 / -0.66%
  • Shares traded1.58m
  • 1 Year change-5.18%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Zhangzhou Pientzehuang Pharmaceutical Co Ltd is a China-based company mainly engaged in drug production and sales. The Company is also engaged in the production and sales of cosmetics and daily chemical products and the circulation of medicine. The Company's core products are PianZi Huang series products, including PianZi Huang, PianZi Huang capsule, compound PianZi Huang buccal tablets, compound PianZi Huang ointment, compound PianZi Huang hemorrhoids ointment and others, covering many fields such as liver disease medication, cold medication, dermatology medication. The Company's products are sold to domestic and overseas markets.

  • Revenue in CNY (TTM)10.91bn
  • Net income in CNY3.08bn
  • Incorporated1999
  • Employees2.79k
  • Location
    Zhangzhou Pientzehuang Pharmaceutical Co LtdNo. 1 Hupo Road, Xiangcheng DistrictZHANGZHOU 363000ChinaCHN
  • Phone+86 5 962301955
  • Fax+86 5 962300313
  • Websitehttps://www.zzpzh.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hansoh Pharmaceutical Group Company Ltd12.11bn4.72bn98.69bn9.10k21.173.5319.288.150.84370.84372.165.060.38041.813.891,425,881.0014.8211.5817.8713.9891.0190.7838.9729.287.81--0.004312.757.695.5226.8511.49-10.45--
Incyte Corp29.53bn235.37m99.18bn2.52k507.684.32113.353.360.140.1418.7916.450.7154.235.761,614,842.000.56989.070.740411.0293.3794.970.796913.681.82--0.010.008.8714.4575.4240.41-15.06--
Cipla Ltd22.77bn3.84bn102.07bn27.76k26.574.1921.514.4855.3955.39328.19351.200.8031.585.089,549,060.0013.5810.0916.4412.4067.0158.6316.9212.662.8269.410.01621.3913.289.5147.1021.9620.6834.08
Royalty Pharma plc16.42bn8.30bn111.94bn89.0010.252.2621.536.822.562.563.8011.630.1337--72.1525,460,710.0010.119.5713.3012.42----75.6467.80----0.425823.475.245.582,549.50-3.8050.99--
Viatris Inc109.04bn-6.40bn113.56bn38.00k--0.79188.211.04-0.7389-0.738912.5416.580.32192.234.94396,013.20-1.890.0887-2.230.106142.4940.29-5.870.28910.96152.370.443560.11-5.146.17-97.37-30.53-16.88--
Astellas Pharma Inc82.61bn2.55bn132.66bn14.75k51.701.8411.351.6130.4230.42986.34854.610.50601.363.39120,113,500.001.564.592.316.6181.7880.533.097.980.862315.320.377486.615.604.19-82.73-40.179.6213.00
Divi's Laboratories Ltd7.40bn1.58bn134.54bn17.50k85.3411.4270.5018.1969.1469.14324.44516.710.57681.134.274,922,286.0012.2916.5513.3218.2259.9156.2421.3126.384.80--0.000634.320.99769.66-12.253.416.4713.40
Teva Pharmaceutical Industries Ltd121.36bn-7.19bn138.60bn35.00k--3.16--1.14-3.26-3.2655.5319.970.40012.054.901,788,132.00-2.99-3.14-4.34-4.2951.0148.14-7.46-9.870.60564.720.7483--6.17-3.4277.15---4.17--
Sandoz Group AG-819.50bn-819.50bn144.04bn23.85k--2.32----------17.20------------------------0.7401--0.3469--7.23---90.92------
Bayer AG357.10bn-6.72bn146.70bn100.87k--0.62832.650.4108-0.8957-0.895747.5831.110.4171.494.49468,688.30-0.7815-1.79-1.06-2.3857.1459.02-1.87-4.800.80592.970.5728---6.115.33-170.87--1.19-47.66
Zhangzhou Pientzhng Phrmctcl Co Ltd10.91bn3.08bn149.08bn2.79k48.4110.63--13.675.105.1018.0823.240.64011.6714.663,911,417.0018.2218.8222.5123.9143.9146.5528.4627.983.64--0.074736.4915.6916.1113.1519.6013.8331.06
Biogen Inc69.62bn11.70bn164.72bn7.57k14.101.3810.042.3711.0711.0765.83112.900.340.86044.581,269,155.005.7112.537.0114.8375.5983.0416.8026.930.80394.890.27780.00-3.32-6.07-61.89-23.58-18.87--
Data as of Nov 21 2024. Currency figures normalised to Zhangzhou Pientzehuang Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

5.03%Per cent of shares held by top holders
HolderShares% Held
China Asset Management Co., Ltd.as of 30 Jun 20246.90m1.14%
Zhong Ou Asset Management Co., Ltdas of 30 Jun 20246.28m1.04%
E Fund Management Co., Ltd.as of 30 Sep 20244.89m0.81%
Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 20243.82m0.63%
GF Fund Management Co., Ltd.as of 30 Jun 20241.97m0.33%
China Universal Asset Management Co., Ltd.as of 30 Jun 20241.80m0.30%
Harvest Fund Management Co., Ltd.as of 30 Jun 20241.74m0.29%
The Vanguard Group, Inc.as of 06 Nov 20241.57m0.26%
First Seafront Fund Management Co., Ltd.as of 30 Jun 2024794.04k0.13%
HuaAn Fund Management Co., Ltd.as of 30 Jun 2024603.14k0.10%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.